Abstract
The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress in the development of inhibitors of sulfur metabolism enzymes.
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design, inhibitors
Infectious Disorders - Drug Targets
Title: Drug Targets in Mycobacterial Sulfur Metabolism
Volume: 7 Issue: 2
Author(s): Devayani P. Bhave, Wilson B. Muse III and Kate S. Carroll
Affiliation:
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design, inhibitors
Abstract: The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress in the development of inhibitors of sulfur metabolism enzymes.
Export Options
About this article
Cite this article as:
Devayani P. Bhave , Wilson B. Muse III and Kate S. Carroll , Drug Targets in Mycobacterial Sulfur Metabolism, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001772
DOI https://dx.doi.org/10.2174/187152607781001772 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
3-Phenyl-1H-Indole-5-Sulfonamides: Structure-Based Drug Design of a Promising Class of Carbonic Anhydrase Inhibitors
Current Pharmaceutical Design Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Tuberculosis of the Thymus: A Case Report and Review of the Literature
Current Respiratory Medicine Reviews Studies on Chemistry, Spectroscopy and Antioxidant Activities of Chromium(III)-Hydrazide Complexes
Medicinal Chemistry ent-Abietane Lactones from Euphorbia
Mini-Reviews in Medicinal Chemistry Substrate Spectra of Nucleoside Phosphorylases and their Potential in the Production of Pharmaceutically Active Compounds
Current Pharmaceutical Design Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets
Current Drug Targets Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms
Current Medicinal Chemistry Structure and Mechanism of Arylamine N-Acetyltransferases
Current Topics in Medicinal Chemistry Design, Synthesis and Antitubercular Evaluation of New 2-amino-5-(4- (benzyloxy)benzyl)thiophene-3-carboxylic Acid Derivatives. Part 3
Letters in Drug Design & Discovery Modulation of Neutrophil Development and Homeostasis
Current Molecular Medicine Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Epitope-Driven TB Vaccine Development: A Streamlined Approach Using Immuno-Informatics, ELISpot Assays, and HLA Transgenic Mice
Current Molecular Medicine Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Preclinical Study of New TB Drugs and Drug Combinations in Mouse Models
Recent Patents on Anti-Infective Drug Discovery Editorial (Thematic Issue: Molecular Determinants of Bacterial Diseases)
Current Medicinal Chemistry Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry